NasdaqGS - Delayed Quote USD

Mersana Therapeutics, Inc. (MRSN)

2.8800 -0.3300 (-10.28%)
At close: April 24 at 4:00 PM EDT
2.8900 +0.01 (+0.35%)
After hours: April 24 at 7:56 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Martin H. Huber M.D. President, CEO & Director 44k -- 1961
Mr. Brian C. DeSchuytner Senior VP, CFO & COO 626.32k -- 1979
Dr. Timothy B. Lowinger Ph.D. Senior VP and Chief Science & Technology Officer 666.3k 199.82k 1964
Ms. Alejandra Veronica Carvajal J.D. Senior VP, Secretary & Chief Legal Officer 606.51k -- 1974
Mr. Mikhail Papisov Ph.D. Co-Founder -- -- --
Mr. Ashish Mandelia Chief Accounting Officer -- -- 1975
Mr. Jason Fredette Senior Vice President of Investor Relations & Corporate Communications -- -- --
Mr. Chuck Miller Senior Vice President of Regulatory Affairs -- -- --
Mr. Marc Damelin Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. -- -- --
Dr. Tushar Misra Ph.D. Senior VP & Chief Manufacturing Officer 485.89k -- 1961

Mersana Therapeutics, Inc.

840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020 https://www.mersana.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
123

Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Mersana Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Mersana Therapeutics, Inc. Earnings Call

Related Tickers

STRO Sutro Biopharma, Inc.
3.4700
-6.72%
 
CTMX CytomX Therapeutics, Inc.
1.6300
-2.98%
 
BCAB BioAtla, Inc.
2.3500
+4.91%
 
ADCT ADC Therapeutics SA
4.7800
-3.82%
 
REPL Replimune Group, Inc.
6.33
-1.40%
 
KZR Kezar Life Sciences, Inc.
0.8014
-2.98%
 
MRUS Merus N.V.
41.97
+2.82%
 
MGNX MacroGenics, Inc.
15.70
-3.27%
 
NUVB Nuvation Bio Inc.
2.6600
-0.75%
 
VTYX Ventyx Biosciences, Inc.
4.2400
-2.53%